GILD Chart

1 Month

	Date	Diff
	2024-04-18	-1.15 %
The U.S. Food and Drug Administration announced that cancer therapies using CAR-T technology, including Gilead Sciences' products like Tecartus and Yescarta, will require changes to their warning labels due to the serious risk of T-cell blood cancer, leading to Gilead Sciences (GILD) stock going down by -1.15% last night. The article discusses the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to the Board of Directors of Vir Biotechnology, Inc., which caused Gilead Sciences' stock to go down as Dr. Bischofberger, a former Executive Vice President at Gilead Sciences, may be leaving Vir's Board to join Kronos Bio, Inc. This change in leadership and potential impact on Vir's direction likely contributed to the decline in Gilead Sciences' stock price.
	2024-04-17	-0.56 %
The article discusses Stoke Therapeutics appointing Jason Hoitt as Chief Commercial Officer, emphasizing his experience in commercial strategies for rare diseases and the potential of their medicine STK-001 for treating Dravet syndrome, attributing the recent stock decline of Gilead Sciences (GILD) to other factors not directly related to the content of the article.
	2024-04-16	-0.65 %
The article discusses the close relationship between U.S. government agencies like the Department of Defense and pharmaceutical companies such as Pfizer and Moderna, highlighting how executives move between these sectors and profit from such connections. The decline in Gilead Sciences (GILD) stock can be attributed to concerns raised in the article about the entwinement of corporations with government institutions, particularly in the pharmaceutical industry. Summary: The article discusses the interconnected relationships between U.S. government agencies, pharmaceutical companies, and industrial corporations, highlighting instances of individuals moving between these sectors. The author draws parallels to historical events and cautions against the influence of the Military-Industrial Complex, especially in the context of the COVID-19 pandemic. Reason for Gilead Sciences(GILD) stock going down: While the article primarily focuses on the relationships between government agencies and corporations, there is a brief mention that during the bird flu scare in 2005, Gilead Sciences benefitted from Defense Secretary Donald Rumsfeld's shares, which raises questions about potential conflicts of interest and ethical considerations that could have contributed to the recent stock decrease.
	2024-04-11	+0.78 %
The article discusses how Gilead Sciences (GILD) stock rose by 0.78% last night due to the announcement made by Citius Pharmaceuticals, Inc. about expanding the ongoing Phase 1 trial of LYMPHIR in combination with CAR-T therapy for treating B-cell lymphomas to include City of Hope, a prestigious cancer treatment and research center. Gilead Sciences (GILD) stock price increased by 0.78% last night, driven by the positive news surrounding other biotech companies in the sector such as Leap Therapeutics and BrainStorm Cell Therapeutics who have announced significant developments in their clinical trials and partnerships. The article discusses how the stock of Gilead Sciences (GILD) went up by 0.78% and mentions that the increase in stock value could be attributed to various institutions like Bleakley Financial Group LLC boosting their positions in Gilead Sciences, along with other hedge funds and institutional investors buying shares of GILD. The article discusses Leap Therapeutics' announcement of a $40 million private placement to fund the development of its lead monoclonal antibody program, DKN-01, with notable participation from Gilead Sciences, Inc., which could have contributed to the increase in Gilead Sciences (GILD) stock as investors view this investment positively for Leap Therapeutics' future prospects in oncology therapeutics.
	2024-04-10	-2.6 %
The article discusses the 12 best depressed stocks to buy in 2024, mentioning various companies like Gilead Sciences, Inc. (GILD) among others, with GILD stock down by -2.6% the previous night. The stock market experienced a decline as JPMorgan Chief Jamie Dimon warned about high stock valuations, geopolitical tensions, and potential rise in interest rates to as much as 8%. The concerns over valuations have led to a selloff, but long-term investors view this as a buying opportunity amidst the ongoing bullish market sentiments. The reason for the decline in Gilead Sciences' stock could be attributed to the broader market trends and concerns highlighted by Dimon regarding the current economic environment and potential future scenarios. The article discusses Compugen Ltd.'s cancer immunotherapy candidate COM503 targeting the IL-18 pathway and its collaboration with Gilead Sciences (GILD). Gilead Sciences (GILD) stock went down by -2.6% due to factors such as uncertainties related to clinical trials, market conditions, and the unproven nature of Compugen's computational drug discovery approach. Summary: Nurix Therapeutics, Inc. announced the extension of their strategic collaboration with Gilead Sciences, presented new case studies, and shared financial results for the first quarter which led to a -2.6% decrease in Gilead Sciences (GILD) stock. Reason for Gilead Sciences (GILD) stock drop: The decrease in Gilead Sciences (GILD) stock may be attributed to various factors such as financial results of Nurix Therapeutics, Inc., potential uncertainties related to the collaboration with Nurix, and overall market conditions.
	2024-04-09	+0.75 %
The article discusses how Gilead Sciences Inc. (GILD) stock rose by 0.75% and provides information about changes in the company's stock ownership, recent insider transactions, financial disclosures, and analyst ratings. The stock likely increased due to various institutional investments and insider activities.
	2024-04-08	-0.23 %
Summary: Ligand Pharmaceuticals Incorporated presented new data on Captisol-enabled™ Topiramate Injection as a potential replacement therapy for certain neurological conditions during the 9th London-Innsbruck Colloquium. Gilead Sciences (GILD) stock went down by -0.23% last night. Answer: Gilead Sciences (GILD) stock may have decreased due to various reasons, including market conditions, investor sentiment, industry news, or company-specific developments, and not necessarily related to the content of the article about Ligand Pharmaceuticals and Captisol-enabled™ Topiramate Injection. The article discusses RedHill Biopharma's corporate transformation towards U.S. government-funded pipeline development, highlighting advanced clinical development programs for drugs like opaganib and RHB-107 focused on nuclear/chemical exposure and viral pandemic scenarios, leading to Gilead Sciences (GILD) stock closing -0.23% down last night. The stock possibly went down due to new developments and focus in the biopharma industry that may have impacted investor sentiment towards Gilead Sciences. The article discusses a study on mRNA-4157 (V940) individualized neoantigen therapy combined with pembrolizumab in patients with HPV-negative head and neck squamous cell carcinoma, showing preliminary positive clinical responses and disease control, with indications of immune response activation, suggesting that the gilead sciences(GILD) stock might have gone down due to the release of this study results impacting investor sentiment. The article announces that Gilead Sciences, Inc. (Nasdaq: GILD) will release its first quarter 2024 financial results and guidance on April 25, 2024, but the stock went down by 0.23% last night; the stock might have declined due to various factors such as market conditions, investor sentiment, or company performance expectations.
	2024-04-05	+0.04 %
Summary: Gilead Sciences (GILD) stock was up 0.04% last night, while Arcus Biosciences, Inc. (NYSE: RCUS) experienced a drop in shares by 2.8%. The increase in Gilead Sciences stock can be attributed to major shareholder Gilead Sciences, Inc. purchasing a significant amount of Arcus Biosciences shares, which may have positively impacted investor sentiment. Reason for Gilead Sciences (GILD) stock increase: Major shareholder Gilead Sciences, Inc. purchased a large number of Arcus Biosciences shares, indicating confidence in the company's future prospects and potentially contributing to the positive performance of Gilead Sciences stock. The article discusses how MacroGenics has achieved progress with its drug vobra duo in treating metastatic castration-resistant prostate cancer, leading to a reduced rate of patient discontinuations in the ongoing phase 2 TAMARACK study, resulting in Gilead Sciences (GILD) stock going up, following the announcement of the positive safety data. The article reports that Ballentine Partners LLC increased their stake in Gilead Sciences by 60.4% in the fourth quarter, which contributed to Gilead Sciences' stock going up by 0.04%; the stock also saw increases in holdings from other large investors, analysts upgrading rating, and a stakeholder selling company shares. Gilead Sciences' stock may have gone up due to increased confidence from these actions of large investors and analysts upgrading the stock to a "strong-buy" rating. The article discusses Deutsche Bank's cautious stance on Bristol-Myers Squibb (NYSE:BMY) stock following the FDA approval of Abecma for the KarMMA-3 trial, citing concerns about its adoption in earlier treatment lines and lack of overall survival benefit compared to standard of care. The rise in Gilead Sciences (NASDAQ:GILD) stock can be attributed to its recent partnership with Tennessee Oncology, which was highlighted as a unique arrangement not typically seen in community practice groups, showcasing potential growth opportunities for investors seeking value.
	2024-04-03	-1.66 %
Summary: Ligand Pharmaceuticals has announced the launch of its subsidiary, Pelthos Therapeutics, with Scott Plesha appointed as CEO to commercialize ZELSUVMI topical gel for molluscum contagiosum treatment, leading to a decline in Gilead Sciences (GILD) stock. Reason for Gilead Sciences (GILD) stock going down: The decline in Gilead Sciences (GILD) stock may not directly be related to the article about Pelthos Therapeutics and ZELSUVMI launch, but rather to broader market conditions, company-specific factors, or other news impacting the pharmaceutical industry.
	2024-04-02	-1.08 %
The article discusses the recent insider selling activity of Gilead Sciences, where the Chief Medical Officer sold 2,000 shares, leading to a 1.08% decrease in the stock price. The sale was part of a pre-arranged trading plan and does not necessarily indicate lack of confidence in the company, as insiders may sell for personal financial management reasons. The article announces the appointment of Mehul Joshi as the Chief Financial Officer of Pulmonx Corporation and highlights his extensive experience in finance, including previous roles at companies like Gilead Sciences. Gilead Sciences (GILD) stock went down by 1.08% possibly due to factors unrelated to this specific announcement, such as market conditions, industry news, or company performance. The article discusses Gilead Sciences (GILD) extending its research collaboration with Nurix Therapeutics, potentially leading to significant future milestones and royalty payments, but the stock went down by -1.08% last night for various market-related reasons.
	2024-04-01	-0.51 %
The article discusses Xilio Therapeutics' pipeline progress and updates, including partnerships with Gilead for tumor-activated therapies, but the stock of Gilead Sciences (GILD) went down likely due to broader market trends or specific company-related factors impacting investor sentiment. The article discusses how Gilead Sciences (GILD) stock experienced a 0.51% decrease last night, attributing this decline to factors such as market volatility, changes in investor sentiment, or company-specific news affecting the stock price.
	2024-03-28	+0.33 %
The article discusses Xilio Therapeutics raising $11.3 million in private-placement financing, and the positive impact on the stock of Gilead Sciences (GILD) by investing $13.5 million in Xilio as part of a licensing agreement, leading to GILD's stock rising by 0.33% due to this investment. The article discusses Xilio Therapeutics' strategic portfolio reprioritization and a private placement agreement with investors, including Gilead Sciences, Inc., contributing to GILD stock's 0.33% increase due to enabling clinical development of promising cancer therapies. The article discusses that Xilio Therapeutics (XLO) stock surged after signing an exclusive license agreement with Gilead Sciences (GILD), causing Gilead stock to increase by 0.33%. Gilead Sciences (GILD) stock went up by 0.33% following an exclusive license agreement with Xilio Therapeutics Inc (XLO) to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301, which helped boost investor confidence and drive the stock price higher. Summary: Gilead Sciences (GILD) stock was up by 0.33% last night due to positive financial results and recent highlights reported by Assembly Biosciences, Inc., including progress on their antiviral pipeline and partnerships. Reason for Gilead Sciences (GILD) stock increase: The positive financial results and recent developments reported by Assembly Biosciences, highlighting progress in their antiviral pipeline and partnership with Gilead, likely contributed to the uptick in Gilead Sciences (GILD) stock.
	2024-03-27	+0.83 %
The article discusses how Gilead Sciences (GILD) stock went up by 0.83% last night, with StockNews.com upgrading its rating from buy to strong-buy, and several analysts providing various ratings and price targets on the stock. The stock likely went up due to positive analyst sentiment and the company's recent quarterly earnings report showing a revenue of $7.12 billion and an earnings per share of $1.72, slightly missing estimates. Additionally, Gilead announced an increase in its quarterly dividend, which may have also contributed to the stock's rise.
	2024-03-26	-0.23 %
The article discusses the recent decrease of 0.23% in Gilead Sciences, Inc. (GILD) stock, citing potential reasons such as varying hedge funds' holdings, mixed ratings from brokerages, recent insider transactions of share selling, and the company's financial performance, including a recent dividend increase and higher payout ratio in the quarter. The article discusses research notes on Arcus Biosciences stock (NYSE:RCUS) by various analysts and the recent activity in its shares, which opened at $16.49 on Monday. The drop in Gilead Sciences (GILD) stock may be due to major shareholder Gilead Sciences, Inc. buying a significant number of shares of Arcus Biosciences' stock, leading to a potential shift in investment focus. The article discusses institutional investments in Gilead Sciences (GILD) stock, with CVA Family Office LLC acquiring shares during the fourth quarter alongside other institutional investors making changes to their positions, while various equities research analysts have downgraded or maintained ratings on the stock; the recent quarterly earnings report of Gilead Sciences showed a decrease in revenue compared to the previous year, leading to a decrease in stock value, and insiders selling company shares may have also impacted the stock's performance.
	2024-03-25	-0.04 %
The article discusses how Kingswood Wealth Advisors LLC increased its holdings in Gilead Sciences, Inc. stock, along with other large investors increasing or reducing their stakes. Gilead Sciences stock is down by 0.04%, with various analysts issuing reports on the stock, leading to a consensus rating of "Hold" and an average price target of $85.36. The decrease in stock value could be due to the recent insider selling and the company's earnings report that missed the consensus estimate, showing a decrease in revenue.
	2024-03-22	-0.66 %
The article discusses Nkarta (NKTX) stock plummeting after the biotech company shifted focus from a cancer drug to an experimental lupus treatment, causing a 31.3% drop in stock price; this news might have impacted Gilead Sciences (GILD) stock negatively, as the company's Kite division is also involved in testing drugs with similar natural killer cells technology used by Nkarta, potentially leading to investor concerns about competition and market demand for similar treatments. Summary: Gilead Sciences (GILD) completed the acquisition of CymaBay Therapeutics, resulting in a decrease in both GAAP and non-GAAP earnings per share (EPS) for 2024 by approximately $3.35 to $3.45, which contributed to the decline in Gilead Sciences stock by -0.66%. Reason for Gilead Sciences (GILD) stock decline: The acquisition of CymaBay Therapeutics and associated costs are expected to result in a decrease in Gilead's earnings per share (EPS) for 2024, leading to the stock decline. The article announces Gilead Sciences' completion of the acquisition of CymaBay Therapeutics, Inc., which is expected to enhance Gilead's liver disease treatment portfolio, but the stock of Gilead Sciences(GILD) experienced a -0.66% decrease likely due to the acquisition costs, associated operating expenses, and lower interest income related to the transaction.
	2024-03-21	-1.2 %
The article reports that Ziegler Capital Management LLC reduced its stake in Gilead Sciences, Inc. stock by 2.8% during the fourth quarter, which contributed to the stock's 1.2% decline. The stock may have gone down due to various hedge funds and institutional investors lowering their stakes, alongside price target reductions and rating downgrades by multiple equities analysts. The article discusses how Raymond James Trust N.A. increased its holdings in Gilead Sciences, Inc. and various other institutional investors acquired shares of the biopharmaceutical company, which led to a drop in their stock price by 1.2%. The stock likely went down due to lowered price targets from analysts and insider selling activities, such as Merdad Parsey selling shares at $73.18 and CFO Andrew D. Dickinson selling shares at $85.78.
	2024-03-19	+0.2 %
The article discusses how Gateway Investment Advisers LLC reduced its stake in Gilead Sciences, Inc. (GILD) by 0.2%, and other institutional investors also adjusted their holdings in the company, with GILD stock rising by 0.2% last night; the increase in Gilead Sciences stock could be attributed to the positive outlook of institutional investors and large stakeholders retaining or increasing their positions in the company, boosting overall market confidence in the stock.
	2024-03-18	-0.58 %
The article discusses Gilead Sciences (GILD) providing an eight-million-dollar grant to the CDA Foundation for Hepatitis B and C care programs, leading to a total distribution of 2.1 million dollars among 14 grantees. The stock might have gone down due to various factors such as market sentiment, profit-taking, or external events impacting the overall stock market, as opposed to the specific news on the grants.
	2024-03-15	-0.7 %
The article discusses how Gilead Sciences (GILD) stock was down -0.7% after being cut by some investors like Sunbelt Securities Inc., who reduced their holdings by 2.1%, and various other large institutional investors. The stock price decrease could be due to insider selling activities, such as by insiders Johanna Mercier and Merdad Parsey, leading to concerns and affecting analysts' ratings and target prices, with some rating changes from buy to hold, which could have contributed to the overall negative sentiment surrounding the stock.
	2024-03-14	-2.28 %
The Gilead Sciences (GILD) stock was down by -2.28% last night. The stock went down due to uncertainties and risks surrounding Gilead and Kite's ability to achieve anticipated financial results, progress on long-term ambitions, revenue acceleration, benefits of acquisitions, clinical trial outcomes, regulatory approvals, commercialization challenges, manufacturing disruptions, pricing pressures, market share erosion, and other risks identified in Gilead's reports filed with the SEC.
	2024-03-12	-0.32 %
The article discusses how Creative Planning increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% and provides details of other hedge funds also adding or reducing their stakes in the company, but GILD stock went down likely due to missing analysts' earnings estimates in the last quarterly report and receiving lower target price ratings by several research firms. The article discusses Gilead Sciences, Inc. (GILD) announcing a quarterly dividend increase, their financial performance, and the recent stock movement being -0.32% down, likely due to analysts lowering price targets and ratings on the stock post-earnings miss, as well as insider selling activities impacting investor sentiment.
	2024-03-11	+0.27 %
The article discusses the performance of NASDAQ dividend stocks and presents a list of 15 best dividend stocks to buy, including Gilead Sciences (GILD), which saw a 0.27% increase in its stock price. Gilead Sciences' stock price likely went up due to the biopharmaceutical company's announcement of a 2.7% increase in its quarterly dividend, marking its ninth consecutive year of dividend growth and resulting in a dividend yield of 4.10% as of March 10. The article discusses the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for Gilead Sciences' cash tender offer for CymaBay Therapeutics, Inc., which has led to a 0.27% increase in Gilead Sciences (GILD) stock; the stock likely went up due to the progress in satisfying the conditions for the tender offer, indicating potential positive developments for Gilead's acquisition of CymaBay. Summary: Gilead Sciences announced the expiration of the Hart-Scott-Rodino waiting period for its cash tender offer for CymaBay Therapeutics, indicating progress towards the acquisition, which likely contributed to the rise in Gilead Sciences' stock price. Reason for Gilead Sciences (GILD) stock going up: The stock likely went up due to positive investor sentiment following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, signaling significant progress in Gilead's cash tender offer for CymaBay Therapeutics.
	2024-03-07	+1.42 %
The article discusses Galapagos NV (NASDAQ:GLPG) being initiated with an Equalweight rating by Morgan Stanley, mentioning cautious optimism due to the company's financial stability and strategic shift towards oncology and cell therapy, leading to uncertainty. Gilead Sciences' (NASDAQ:GILD) decision regarding Galapagos' programs is highlighted as a crucial factor impacting market performance.
	2024-03-06	-0.49 %
The article discusses positive Phase 2 study data from Gilead Sciences and Merck & Co. on a combination regimen for an oral HIV treatment, which has caused excitement in the market, but despite the positive news, Gilead Sciences' stock was down -0.49% last night, potentially influenced by broader market conditions or specific investor reactions to the company's performance or outlook. The article discusses Gilead Sciences' (GILD) stock being down by -0.49% last night due to the presentation of Phase 2 clinical study results on a potential long-acting oral combination treatment option for HIV involving islatravir and lenacapavir, which showed promising data but also revealed some treatment-related adverse events, leading to a slight decrease in the stock value. The article discusses Compugen Ltd.'s financial results and partnerships, highlighting its strong cash position and promising clinical trials. Although no specific information is provided about why Gilead Sciences (GILD) stock went down, factors such as market conditions, industry trends, announcements from other companies, or broader economic factors could have influenced the stock's decline. Summary: Gilead Sciences and Merus have entered into a research collaboration, option, and licensing deal to develop novel dual tumor-associated antigens targeting trispecific antibodies, potentially leading to a reduction in Gilead's 2024 earnings. Reason for GILD stock going down: The stock likely went down due to the announcement of the collaboration deal with Merus, which may decrease Gilead's earnings in 2024 by 3 to 5 cents per share.
	2024-03-05	+1.02 %
Summary: Compugen Ltd., a clinical-stage cancer immunotherapy company, reported financial results for the fourth quarter and full year 2023, highlighting their progress and milestones achieved during the year. Reason for Gilead Sciences (GILD) Stock Increase: Gilead Sciences stock went up last night because Compugen, a cancer immunotherapy company, reported significant progress in 2023, including a license agreement with Gilead Sciences for their preclinical potential first-in-class antibody program, COM503, reflecting Compugen's computational discovery, research, and development capabilities. The agreement involved an upfront payment of $60 million and an additional $30 million near-term milestone payment, showcasing the potential value creation and partnerships driving the stock movement. The article discusses Truist Securities' positive outlook on Arcellx Inc. (NASDAQ: ACLX), raising the price target due to confidence in its CAR-T therapy Anito-cel and highlighting the potential for it to lead in the BCMA CAR-T space, supported by its partner Gilead Sciences. The increased price target and Buy rating are based on updated sales forecasts and the belief that Anito-cel could be a top choice among BCMA CAR-T therapies, leading to a rise in the stock price forecast. Gilead Sciences (GILD) stock was up 1.02% last night, and the stock likely rose due to positive news or developments related to the company's business or financial performance. Opaganib, a novel oral drug being evaluated as a medical countermeasure against Sulfur Mustard exposure, was selected by the U.S. government, causing Gilead Sciences (GILD) stock to go up by 1.02% as it is being developed for diverse indications, including COVID-19, acute respiratory distress syndrome, and oncology, as well as demonstrating positive results in various studies. Gilead Sciences (GILD) stock was up by 1.02% last night, and the increase might be attributed to new data presentations at a conference highlighting the efficacy and safety of Veklury, Gilead's antiviral medication for COVID-19, including its potential benefits in reducing mortality and lowering the risk of long-COVID symptoms.
	2024-03-04	-0.08 %
The article discusses Ligand Pharmaceuticals Incorporated granting a non-qualified stock option award to an employee, which does not directly relate to the stock movement of Gilead Sciences (GILD); however, GILD stock went down by -0.08% last night possibly due to factors such as market conditions, investor sentiment, or company-specific news. This article discusses President Joe Biden's administration urging a U.S. appeals court to maintain a federal mandate requiring health insurers to cover preventive care services, including HIV-preventing medication and cancer screenings at no added cost to patients. The lawsuit in question is brought by businesses, including Braidwood Management, objecting to the requirement to provide coverage for HIV pre-exposure prophylaxis (PrEP), which they argue goes against their religious beliefs. Gilead Sciences, known for manufacturing PrEP drugs, is involved in this case. If the ruling stands, insurers could start charging co-pays and deductibles for preventive services. The stock of Gilead Sciences (GILD) went down, possibly due to the ongoing legal implications surrounding the coverage mandate and the potential impact on the company's products and services. The article discusses President Joe Biden's administration urging a U.S. appeals court to keep a federal mandate requiring health insurers to cover preventive care services like HIV prevention drugs. The mention of HIV-preventing medication, which includes products made by Gilead Sciences, could have influenced the company's stock to decline by 0.08% due to potential legal challenges impacting their products and business.
	2024-02-29	-0.83 %
The article discusses Halper Sadeh LLC investigating various companies like CymaBay Therapeutics, Inc., Societal CDMO, Inc., and Everi Holdings Inc. for potential violations of securities laws and breaches of fiduciary duties, and offers legal assistance to shareholders. Gilead Sciences' stock declined by -0.83% the previous night. GILD stock might have gone down due to various factors affecting the market, such as overall market conditions, company announcements, earnings reports, or analyst recommendations. The article discusses Nvidia's impressive financial performance, with record-breaking profits and revenue, leading to high expectations for the company's future growth. As for Gilead Sciences (GILD) stock going down, it is not directly addressed in the article, but it could be influenced by various factors such as market conditions, company-specific news, or investor sentiment. The article discusses various investigations into acquisitions involving different companies like CymaBay Therapeutics, Everi Holdings Inc., Sterling Check Corp., and Societal CDMO Check Corp., conducted by Brodsky & Smith LLC; the reason for Gilead Sciences (GILD) stock going down was not directly related to the content of the article but could be influenced by market conditions, company performance, or other external factors.
	2024-02-28	-0.44 %
The article discusses how Connor Clark & Lunn Investment Management Ltd. increased its stake in Gilead Sciences, Inc. by 70.3% during the 3rd quarter, and other hedge funds also modified their holdings in the company. Gilead Sciences’ stock experienced a decrease of -0.44% last night, possibly due to its recent quarterly earnings missing estimates. The article provides information related to Arcus Biosciences, Inc. and its recent activities, such as analyst estimates, earnings reports, stock ratings, and insider transactions. Gilead Sciences(GILD) stock went down last night possibly due to Arcus Biosciences, Inc.'s negative financial results and subsequent analyst estimates, which impacted Arcus Biosciences stock price and potentially influenced Gilead Sciences stock as well. The article discusses Gilead Sciences' proposed acquisition of CymaBay Therapeutics for $4.3 billion, with CymaBay focusing on developing therapies for liver and chronic diseases, potentially impacting Gilead's stock negatively due to uncertainties surrounding the pending acquisition and related potential risks and conditions. The article discusses biotech stocks and highlights companies within the biotechnology sector, including Gilead Sciences (GILD) which saw its stock down by -0.44% last night. Biotech stocks offer opportunities for significant returns but also carry risks such as regulatory hurdles, clinical trial failures, and market volatility, which could have contributed to Gilead Sciences stock going down.
	2024-02-27	+0.1 %
The article discusses the increase in Gilead Sciences (GILD) stock by 0.1% recently, attributed to Cary Street Partners Investment Advisory LLC raising its position in shares of Gilead Sciences, Inc. The increase in stock value can be linked to various hedge funds modifying their holdings, such as Altshuler Shaham Ltd, Nilsine Partners LLC, Lansing Street Advisors, Rodgers Brothers Inc., Peddock Capital Advisors LLC, and others, resulting in an increase of institutional ownership. Furthermore, despite several price target reductions by research analysts, Gilead Sciences' stock currently holds a consensus rating of "Hold" with an average price target of $85.86. The article discusses Ligand Pharmaceuticals' financial results for Q4 2023 and the full year, highlighting increased revenues and net income. Gilead Sciences (GILD) stock went up 0.1% last night, potentially due to Ligand's positive financial performance signaling a strong pharmaceutical sector. Gilead Sciences (GILD) stock had a small increase of 0.1% last night after the company announced providing $12.6 million in grant funding to 19 organizations through its new Setting the P.A.C.E. initiative aimed at improving HIV prevention, anti-stigma efforts, and health equity for Black cisgender and Transgender women and girls, who are disproportionately impacted by the HIV epidemic, thus positively influencing the stock. The article discusses how Natixis Advisors L.P. reduced its stake in Gilead Sciences, Inc. and provides information about the company's recent financial data, including quarterly earnings and dividend announcements, as well as insider stock sales; the slight increase in Gilead Sciences stock price could be due to various institutional investors and hedge funds making modifications to their holdings of the stock, signaling positive investor sentiment.
	2024-02-26	-0.82 %
The article discusses Swiss National Bank increasing its position in Arcus Biosciences, Inc (NYSE:RCUS) and Gilead Sciences, Inc. buying shares of Arcus Biosciences, leading to a decrease in Gilead Sciences (GILD) stock, possibly due to investment diversification or strategic business decisions. The recent -0.82% decline in Gilead Sciences (GILD) stock could be attributed to the announcement of the expansion of their HIV treatment Biktarvy to include individuals with suppressed viral loads and known or suspected M184V/I resistance, which highlights the permanent and irreversible nature of HIV treatment resistance that can limit future treatment options. The article discusses how Parkside Financial Bank & Trust increased its stake in Gilead Sciences, Inc. stock by 7.3% during the 3rd quarter, where other investors also acquired positions, but Gilead's stock saw a decrease likely due to lower than expected earnings reported on Feb 6th and changes in analyst ratings, with the stock being down by -0.82% last night. Gilead Sciences stock (GILD) went down by -0.82% last night despite a presentation of new clinical data and real-world evidence at the 31st Conference on Retroviruses and Opportunistic Infections, discussing various antiviral research and development programs across HIV, COVID-19, and viral hepatitis, which reflected the company's commitment to addressing global needs, including factors associated with hepatitis B treatment response in adults with HIV/HBV coinfection, investigational treatment candidates, and the impact of Veklury on mortality and long-COVID. The stock decline could be influenced by various factors, such as market conditions, investor sentiment, or company performance beyond the presented data.
	2024-02-23	+1.06 %
The article reports that Gilead Sciences (GILD) stock was up 1.06% and highlights WINTON GROUP Ltd acquiring a stake in the company, alongside other hedge funds making changes to their positions, leading to an increase in institutional ownership. The stock goes up due to increased investor interest and acquisitions by various funds.
	2024-02-22	-0.57 %
The article discusses Sanofi's (SNY) Board of Directors' proposal to appoint Clotilde Delbos, Anne-Françoise Nesmes, and John Sundy as independent directors, with the Chairman expressing appreciation for outgoing members and highlighting the new directors' expertise in finance and science, particularly in immunology. Gilead Sciences (GILD) stock went down last night by -0.57%, possibly due to various factors influencing the market's perception of the company's performance and future prospects. The article discusses Gilead Sciences (GILD) stock, which experienced a 0.57% decrease last night, and the reason for the stock going down is not mentioned in the provided content which mainly focuses on an in-depth resource regarding the COVID-19 crisis and related issues. The article discusses Ligand Pharmaceuticals Incorporated collaborating with Eisai Co., Ltd. to obtain marketing authorization approval for the injection formulation of Fycompa® in Japan in January 2024, highlighting the role of Ligand's Captisol® technology in drug development; however, it does not mention the reason for the decline in Gilead Sciences (GILD) stock.
	2024-02-21	+1.61 %
The article discusses how Gilead Sciences (GILD) stock has lagged behind the broader markets but recently went up by 1.61%, prompting the question of whether this high-yield dividend stock is a good buy currently. The stock likely went up due to various factors such as positive news, earnings reports, or market speculation.
	2024-02-20	+0.64 %
The article discusses the developments and advancements of IDEAYA Biosciences, Inc. in precision medicine oncology, specifically highlighting programs such as darovasertib, IDE397, IDE161, and GSK101, leading to a positive collaboration with Gilead Sciences and resulting in Gilead Sciences stock going up by 0.64%. The article discusses how Robertson Stephens Wealth Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the 3rd quarter, which could have contributed to GILD stock going up by 0.64% last night as institutional investors and hedge funds modified their holdings of GILD.
	2024-02-16	-2.44 %
Gilead Sciences' stock went down because the company paused tumor study enrollment and the FDA requested a partial clinical hold on their trials. Gilead Sciences (GILD) stock went down by -2.44% last night, and the reason for the decline is not mentioned in the article. Gilead Sciences (GILD) stock went down by -2.44% because Ligand Pharmaceuticals, a biopharmaceutical company, announced the appointment of two executives to strengthen their commercial and clinical expertise, which may impact Gilead's competitive position in the industry.
	2024-02-15	+0.45 %
Compugen announced the appointment of Michelle Mahler as Chief Medical Officer, effective March 1, 2024, which has potentially contributed to the increase in Gilead Sciences (GILD) stock as Michelle has been leading the preparation of the COM503 Phase 1 study, a program recently partnered with Gilead Sciences.
	2024-02-14	-0.67 %
An article discusses the recent adjustment of Gilead Sciences' stock price target by RBC Capital, noting that the company has faced challenges in diversifying into the oncology market, limiting near-term potential for stock appreciation.
	2024-02-13	-1.24 %
The article does not provide any information about why Gilead Sciences (GILD) stock went down.
	2024-02-12	+1.06 %
Gilead Sciences stock went up by 1.06% last night after the company announced its agreement to acquire CymaBay Therapeutics for $4.3 billion, which includes CymaBay's lead product candidate, seladelpar, for primary biliary cholangitis (PBC) treatment, adding to Gilead's existing liver portfolio. The article is about a law firm investigating potential violations by various companies, including Gilead Sciences (GILD), but it does not explain why Gilead Sciences' stock went up. Gilead Sciences' stock went up 1.06% after the company agreed to acquire CymaBay Therapeutics for $4.3 billion. Gilead Sciences (GILD) stock went up 1.06% last night after the announcement of its acquisition of liver disease drugmaker CymaBay for $4.3 billion, as CymaBay's seladelpar has shown potential in treating primary biliary cholangitis (PBC), a liver disease. The article discusses an investigation by Halper Sadeh LLC into whether the sale of CymaBay Therapeutics to Gilead Sciences for $32.50 per share is fair to CymaBay shareholders. The investigation aims to determine if CymaBay and its board of directors violated federal securities laws and breached their fiduciary duties by not obtaining the best possible consideration for shareholders and not disclosing all material information. It does not provide any information regarding why Gilead Sciences' stock went up. Gilead Sciences' stock went up 1.06% last night, and the reason behind this increase is not mentioned in the article.
	2024-02-09	-0.18 %
Gilead Sciences (GILD) stock went down by -0.18% last night, the reason for the decline is not mentioned in the article.
	2024-02-08	-0.83 %
The article states that shares of Kyverna Therapeutics, a biopharmaceutical company backed by Gilead Sciences, rose 55.7% in their market debut, resulting in a market capitalization of $1.4 billion. The article does not provide a specific reason for the decline in Gilead Sciences' stock. The article announces that Assembly Biosciences, Inc. (Nasdaq: ASMB) expects a reverse stock split of its outstanding shares to take effect, which may have caused Gilead Sciences' stock to go down.
	2024-02-07	-4.25 %
The article does not mention why Gilead Sciences (GILD) stock went down. The article discusses Great Lakes Advisors LLC's 20% reduction in its holdings of Gilead Sciences (GILD) stock, which may have contributed to the stock's 4.25% decrease.
	2024-02-06	+1.32 %
The article discusses a decrease in the holdings of Gilead Sciences, Inc. by Dorsey & Whitney Trust CO LLC and the buying and selling of shares by other large investors. The reason for the increase in Gilead Sciences' stock is not mentioned in the article. Gilead Sciences (GILD) stock went up by 1.32% due to a strong year of revenue growth, driven by HIV and oncology sales, providing a solid foundation as the company enters a new catalyst-rich phase with several milestones expected in 2024, including updates on long-acting HIV prevention and treatment, Cell Therapy, and Trodelvy. The article does not specifically mention Gilead Sciences (GILD) stock going up by 1.32% last night. Therefore, it cannot answer why the stock went up. The Gilead Sciences (GILD) stock went up by 1.32% due to China's panicky markets staging a sharp rally, reports of government intervention, and a leveling off in US Treasury yields.
	2024-02-05	-0.32 %
The article compares the stocks of Merck & Co., Inc. and Ultragenyx Pharmaceutical, stating that Ultragenyx Pharmaceutical is considered more favorable due to its stronger consensus rating and higher potential upside according to analysts. The article does not provide any information about why Gilead Sciences (GILD) stock went down. The article discusses J.P. Morgan Private Wealth Advisors acquiring a new position in Gilead Sciences stock, as well as other hedge funds and institutional investors modifying their holdings. The stock went down by -0.32%. The reason for the stock going down is not mentioned in the article. Gilead Sciences (GILD) stock went down by -0.32% last night, and the reason for the decrease is not mentioned in the article provided. Gilead Sciences (GILD) stock went down last night because investors are eagerly awaiting the company's upcoming earnings report, which will provide valuable insights into its financial performance and help make investment decisions.
	2024-02-02	-1.54 %
In an article posted on February 2nd, 2024, Gilead Sciences (GILD) stock was reported to have dropped by 1.54%. The reason for the drop in the stock price is not mentioned in the article. Gilead Sciences (GILD) stock went down by -1.54% last night, potentially due to the purchase of a significant number of shares of Arcus Biosciences, Inc. (NYSE: RCUS) by major shareholder Gilead Sciences, Inc.
	2024-02-01	-0.13 %
Gilead Sciences' stock went down -0.13% last night, but the article does not provide a specific reason for the decline. Ligand Pharmaceuticals has granted stock options and restricted stock units to two non-executive employees, which may have caused a decline in Gilead Sciences' stock.
	2024-01-30	-0.57 %
Gilead Sciences' stock (GILD) went down 0.57% last night; the reason for the decline was not specifically mentioned in the article. Gilead Sciences (GILD) stock went down by -0.57% due to a decrease in stake by Cornerstone Wealth Management LLC and other institutional investors. Gilead Sciences stock went down because they announced an equity investment and collaboration amendment with Arcus Biosciences, which caused uncertainty among investors. Gilead Sciences (GILD) stock went down 0.57% last night, and the reason behind this decline is not mentioned in the article.
	2024-01-29	-0.57 %
Gilead Sciences' stock went down by -0.57% due to an amendment in its collaboration agreement with Arcus Biosciences, as well as a separate equity investment of $320 million by Gilead in Arcus common stock at $21.00 per share. Gilead Sciences (GILD) stock went down because the company announced an amendment to their collaboration agreement with Arcus Biosciences and a separate equity investment of $320 million, which raised Gilead's ownership stake in Arcus to 33%. This investment will accelerate the growth of their joint development programs and focus on advancing the Phase 3 studies of their cancer treatments. Gilead Sciences (GILD) stock went down by -0.57% due to the company's decision to discontinue a late-stage trial for their candidate domvanalimab in combination with another experimental drug to treat a type of non-small cell lung cancer and their reprioritization of their development program. The article discusses Aveo Capital Partners LLC's increased holdings in Gilead Sciences, Inc., a biopharmaceutical company, and provides an overview of Gilead Sciences' stock. The reason for Gilead Sciences' stock going down is not mentioned in the article.
	2024-01-26	-0.88 %
The article reports that Gilead Sciences' stock went down by 0.88%, and the reason for this decline is not mentioned in the article.
	2024-01-25	+0.88 %
The article compares Gilead Sciences (GILD) and Ambrx Biopharma (AMAM) stocks based on various factors such as profitability, dividends, earnings, valuation, risk, analyst recommendations, and institutional ownership. Gilead Sciences' stock has gone up by 0.88% and is considered more favorable than Ambrx Biopharma due to higher revenue and earnings, as well as stronger institutional ownership.
	2024-01-23	+1.34 %
The article explains that Gilead Sciences had a rough day on the stock exchange due to disappointing clinical trial results for one of its investigational medications, causing its stock price to fall by over 10%, but it doesn't provide a reason for the recent increase in the stock price. The article announces that Gilead Sciences will be releasing its fourth quarter and full year 2023 financial results and guidance, which has caused a 1.34% increase in the company's stock. The article states that Gilead Sciences (GILD) stock went up by 1.34% last night, but does not provide a reason for the increase.
	2024-01-22	-10.15 %
Gilead Sciences' stock went down by 10.15% after the company announced that a Phase 3 trial testing its drug Trodelvy in certain lung cancer patients did not improve overall survival as expected. Gilead Sciences (GILD) stock went down by 10.15% due to the failure of a trial for the company's experimental lung cancer treatment. The stock of Gilead Sciences (GILD) went down by 10.15% due to the failure of a late-stage trial of its antibody-drug conjugate, Trodelvy, to significantly improve survival for previously treated patients with advanced non-small cell lung cancer (NSCLC). Gilead Sciences (GILD) stock fell by 10.7% after the company's late-stage trial of its antibody-drug conjugate Trodelvy failed to show a significant improvement in survival for patients with a certain type of lung cancer. The trial did not meet its primary endpoint of overall survival, although there was a small difference in median overall survival favoring Trodelvy in a subgroup of patients. Some analysts believe that the stock's decline is an overreaction, as Gilead's long-term growth story in the HIV sector remains intact. The article states that Gilead Sciences' stock went down by 10.15% last night due to the announcement that their Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer. Shares of Gilead Sciences Inc. (GILD) fell 9.7% after the company reported disappointing results from its lung cancer trial, in which its antibody-drug conjugate Trodelvy failed to meet its primary endpoint of overall survival in patients with previously treated metastatic non-small-cell lung cancer.
	2024-01-17	+0.57 %
The article announces the appointments of Habib Dable and Dr. William Grossman to the Board of Directors of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company, which may have contributed to the increase in Gilead Sciences (GILD) stock.
	2024-01-16	-0.45 %
Gilead Sciences (GILD) stock went down by 0.45% last night, and the reason for this decline is not mentioned in the article.
	2024-01-12	+1.16 %
The article states that the European Union's drug watchdog is conducting a safety review into cancer cell therapies made by companies such as Novartis and Gilead Sciences, which may explain the increase in Gilead Sciences' stock.
	2024-01-10	-1.81 %
The article does not mention anything about Gilead Sciences (GILD) stock going down. Gilead Sciences' stock went down because a California court ruled that the company could face claims of negligence over a delay in releasing a safer treatment for HIV. The article suggests that Gilead Sciences' stock went down last night by 1.81%, and it explains that although the stock did not perform well in 2023, it may see a rally in 2024 due to the company's important scientific work and strong financials.
	2024-01-05	-1.38 %
The article discusses the approval of ZELSUVMI (berdazimer topical gel) by the U.S. Food and Drug Administration (FDA) for the treatment of molluscum contagiosum. The approval of this novel drug is the reason why Gilead Sciences (GILD) stock went down.
	2024-01-04	+1.2 %
The article discusses Assembly Biosciences' anticipated milestones and progress for its clinical pipeline in 2024, which includes plans to initiate clinical studies for four development candidates, leading to a positive impact on Gilead Sciences' stock.
	2024-01-02	+2.75 %
The article announces that Galapagos NV and Alfasigma S.p.A have signed an agreement to transfer Galapagos' Jyseleca® (filgotinib) business to Alfasigma, resulting in the company's stock, Gilead Sciences (GILD), going up by 2.75%.
	2023-12-27	+0.53 %
The article discusses predictions for the Bank of Canada's interest rate cuts in 2024, which are expected to have an impact on mortgage rates and various investment sectors. It is predicted that Gilead Sciences (GILD) stock, a company in the healthcare sector, may experience some strength or recovery as a result of the interest rate cuts.
	2023-12-26	+0.36 %
The article announces the appointment of James Bucher as Chief Legal Officer and the promotion of Wendy Chang to Chief People Officer at Harpoon Therapeutics, a clinical-stage immunotherapy company; the stock price of Gilead Sciences (GILD) went up last night and the reason for the increase in stock price is not mentioned in the article. The article discusses the appointment of James Bucher as Chief Legal Officer and the promotion of Wendy Chang to Chief People Officer at Harpoon Therapeutics. The article does not provide any information about why Gilead Sciences (GILD) stock went up.
	2023-12-21	+0.43 %
Summarized article: Gilead Sciences (GILD) stock went up 0.43% as the company purchased 15 million shares of HOOKIPA Pharma's (HOOK) common stock for approximately $21.25 million and showed optimism about their partnership in finding a potential functional cure for HIV, with a Phase 1 trial set to begin in the first half of next year. Gilead Sciences (GILD) stock went up by 0.43% after the company announced that its executives will be speaking at an investor conference, indicating potential positive news or opportunities for the company. Gilead Sciences (GILD) stock went up because the company purchased 15 million shares of HOOKIPA Pharma's (HOOK) common stock for approximately $21.25 million, showing confidence in HOOKIPA's immunotherapeutic platform and their partnership to find a potential functional cure for HIV. Gilead Sciences stock has increased by 0.43% and investors anticipate the recovery of the company that suffered a blowup in 2016.
	2023-12-20	-1.13 %
RedHill Biopharma announced that its investigational drugs, opaganib and RHB-107, showed a strong synergistic effect when combined with remdesivir in an Ebola virus study, improving viral inhibition without increasing toxicity, and these drugs are also expected to be effective against emerging viral variants, including COVID-19; however, the article does not provide information on why Gilead Sciences (GILD) stock specifically went down. The article discusses a study conducted by the U.S. Army, funded by RedHill Biopharma Ltd, which indicates that the combination of opaganib and RHB-107 with Gilead Sciences' Veklury (remdesivir) has shown robust synergistic effects in inhibiting the Ebola virus. The reason for Gilead Sciences' stock going down might be unrelated to this study.
	2023-12-19	-0.01 %
Gilead Sciences (GILD) stock went down 0.01% after the company announced an agreement with Compugen Ltd. to exclusively license its potential anti-IL-18 binding protein antibody program for the treatment of various tumor types, resulting in a reduction of Gilead's GAAP and non-GAAP 2023 EPS by approximately $0.03 -$0.05. The article is about Gilead Sciences (GILD) stock going down by -0.01% last night, and the reason for the decline is not mentioned in the article. Gilead Sciences' stock went down last night due to an announcement of the company's agreement with Compugen Ltd to license a pre-clinical antibody program, including the COM503 drug candidate. Gilead Sciences (GILD) stock went down by 0.01% after the company agreed to buy exclusive rights from Compugen Ltd. for the development and commercialization of anti-IL-18 binding protein antibodies for cancer treatment, valued up to $848 million, including milestone payments, while Compugen's stock surged by 151% due to the deal.
	2023-12-14	-1.58 %
The article announces the appointment of three new members to Envista Holdings Corporation's leadership team, including Robert Befidi as President, Diagnostics; Suraj Satpathy as Chief Human Resources Officer; and Andrew Chen as Chief Information Officer, however it does not provide any explanation for the decline in Gilead Sciences stock.
	2023-12-12	+0.91 %
The article discusses Ligand Pharmaceuticals Incorporated's Investor and Analyst Day, where the company's CEO Todd Davis and senior management provided an overview of the business model and investment selection process, as well as introduced the company's 2024 guidance. The stock of Gilead Sciences (GILD) went up by 0.91% last night, but the article does not provide a specific reason for this increase. Gilead Sciences (GILD) stock went up 0.91% last night, but the article does not provide an explanation for why this happened. The article primarily focuses on the power and potential of technology stocks in shaping investment portfolios. It highlights the benefits of owning tech stocks, their ability to drive substantial growth, and the dynamic nature of the tech industry. The article also discusses some top tech stocks for 2024, including Electronic Arts, Meta (formerly known as Facebook), Tencent Holdings, Amazon, Apple, and Nvidia. It provides insights into these companies' strengths and potential risks for investors to consider.
	2023-12-11	+1.35 %
Gilead Sciences' stock went up by 1.35% last night, and the reason behind the increase is the company's recognition as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year, highlighting the company's commitment to sustainable business practices and transparency.
	2023-12-06	+0.43 %
The article does not provide any information about why Gilead Sciences (GILD) stock went up, and instead focuses on Ligand Pharmaceuticals hosting an investor and analyst day.
	2023-12-04	+0.89 %
Gilead Sciences (GILD) stock went up by 0.89% after it announced a clinical study collaboration and supply agreement with IDEAYA Biosciences to evaluate the combination of IDE397 and Gilead's sacituzumab-govitecan-hziy ("Trodelvy") in a Phase 1 clinical trial for MTAP-deletion bladder cancer, which represents a high unmet medical need with no approved therapies.
	2023-11-28	-0.55 %
Gilead Sciences (GILD) stock went down -0.55% due to the U.S. Food and Drug Administration investigating reports of T-cell malignancies in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies, which includes Gilead's Yescarta product. Gilead Sciences (GILD) stock went down last night due to the U.S. Food and Drug Administration investigating CAR T cancer therapies, including Gilead's own Tecartus and Yescarta, for potentially causing a type of white blood cell to become cancerous in patients who received the treatment. This article announces the launch of Amazon Q, a generative AI-powered assistant specifically designed for work, which allows customers to get fast and relevant answers to questions, generate content, and take actions informed by their organization's information repositories, code, and enterprise systems. Gilead Sciences' stock went down, but the article does not provide any information on why this happened.
	2023-11-27	-0.61 %
The article discusses the downfall of director Carl Erik Rinsch's television project, which resulted in a loss of $55 million for Netflix. Rinsch allegedly mismanaged the project, overspent the budget, and engaged in erratic behavior. He also invested a significant amount of money in Gilead Sciences stock and lost a substantial portion of it, further contributing to the financial loss.
	2023-11-24	-0.42 %
Film director Carl Erik Rinsch was fired for diverting funds from a Netflix production to gamble on stocks and cryptocurrencies, including Dogecoin, resulting in losses of millions of dollars, causing his stock bets on Gilead Sciences to go down.
	2023-11-16	-0.69 %
The article provided does not provide any information about Gilead Sciences (GILD) stock or the reason for its decline. This article appears to be unrelated to Gilead Sciences and its stock performance.
	2023-11-15	+0.43 %
Gilead Sciences' stock went up by 0.43% after announcing a $200 million equity investment in Arcellx Inc., which will give Gilead a 13% stake in the company and extend Arcellx's cash runway. Gilead Sciences' stock went up by 0.43% as the company invested another $200 million in Arcellx, a clinical-stage biotechnology company, to expand their collaboration and include lymphomas, with Gilead's Kite unit exercising its option to negotiate a license for Arcellx's ARC-SparX program. Arcellx stock rose more than 10% in premarket trading after Gilead Sciences announced an extension of their collaboration, which includes a $200 million equity investment at a premium price, increasing Gilead's stake in Arcellx to approximately 13%. In one sentence, the article discusses how Gilead Sciences' stock went up by 0.43% due to their deepened collaboration with Kite division in cancer treatments, specifically focusing on multiple myeloma and lymphomas. Gilead Sciences (GILD) stock went up by 0.43% following the announcement of a $200 million investment in its partnership with Arcellx. The increase in stock can be attributed to the positive news of further investment in a biotechnology collaboration.
	2023-11-09	-3.75 %
The article discusses the unaudited half-year results of The Biotech Growth Trust PLC and mentions that the company's NAV (Net Asset Value) per share declined by 4.1% during the period, underperforming the NASDAQ Biotechnology Index. The decline in the company's stock is attributed to various factors, including the challenging economic environment, disappointing trial results from some portfolio holdings, and the write-down of a direct private investment. Additionally, the presence of gearing and the macroeconomic conditions also impacted the performance of the stock.
	2023-11-08	-3.36 %
Gilead Sciences (GILD) stock went down by -3.36% because investors were weighing comments from Federal Reserve officials and some see the market getting ahead of itself when it comes to the potential for easing by the Federal Reserve. The article discusses various stock movements, including Gilead Sciences (GILD), which declined by 5%. The reason for the decline is not mentioned in the article. Gilead Sciences (GILD) stock went down -3.36% due to weak revenue and slashed production goals of luxury EV maker Lucid.
	2023-11-07	-0.65 %
The Gilead Sciences (GILD) stock went down because of concerns about a wall of government debt that will be with us for decades and the potential impact it could have on the economy and financial markets. Gilead Sciences (GILD) stock went down by 0.65% following its strong sales performance in oncology. The decline may be attributed to other factors affecting the overall market or investor sentiment. The article announces that William Collier will retire as President and CEO of Arbutus Biopharma Corporation at the end of 2023, and Michael J. McElhaugh will serve as Interim CEO starting January 1, 2024; the reason for Gilead Sciences (GILD) stock going down is not mentioned in the article. Gilead Sciences (GILD) stock went down by 0.65% last night despite the company posting better-than-expected financial results, as increased sales in oncology and HIV were offset by lower sales of other products. The article discusses the recent decline in Gilead Sciences (GILD) stock and attributes it to a renewed slide in oil prices, where U.S. crude fell below $80 per barrel for the first time since August after disappointing Chinese export readings. Gilead Sciences' stock went down by -0.65% after the company raised its outlook for 2023, with increased sales and earnings estimates. The reason for the stock decrease is not mentioned in the article.
	2023-11-06	-0.55 %
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced that preliminary data from the Phase 2 EDGE-Gastric study showed positive results for their domvanalimab plus zimberelimab and chemotherapy combination in treating gastric cancer, which will be presented at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series; the decline in Gilead Sciences stock could be due to general market fluctuations or investor reaction to the clinical trial results. Gilead Sciences (GILD) stock went down by -0.55% last night due to investors reassessing market valuations following a fall in bond yields. Gilead Sciences (GILD) stock went down by 0.55% due to a preliminary analysis from the Phase 2 EDGE-Gastric study, which showed encouraging results for the combination of domvanalimab plus zimberelimab and chemotherapy in the treatment of gastric, gastroesophageal junction, or esophageal adenocarcinoma.
	2023-11-03	+0.44 %
Gilead Sciences (GILD) stock went up by 0.44% after the company announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases. The data includes findings from studies on the safety and efficacy of Hepcludex® (bulevirtide) in patients with chronic hepatitis delta virus (HDV), as well as long-term results from ongoing studies of Vemlidy® (tenofovir alafenamide, TAF) in chronic hepatitis B (HBV). The stock went up due to positive results and demonstrations of the company's efforts to address the unmet needs of people affected by viral hepatitis.
	2023-11-02	+1.3 %
Gilead Sciences (GILD) stock went up by 1.3% after the company announced that it will be presenting 29 presentations, including 10 oral presentations, at the 65th American Society of Hematology Annual Meeting and Exposition. The presentations will showcase new data supporting the long-term survival and durability of response of their CAR T-cell therapies in blood cancers, across lines of therapy and age groups.
	2023-11-01	+2.1 %
Gilead Sciences (GILD) stock went up 2.1% after Ligand Pharmaceuticals announced its acquisition of Tolerance Therapeutics, the company that invented TZIELD, the first FDA-approved treatment to delay the onset of Stage 3 type 1 diabetes, which is marketed by Sanofi following its acquisition of Provention Bio.
	2023-10-31	+0.99 %
Gilead Sciences (GILD) stock went up by 0.99% last night, but the given article does not mention or provide any information about GILD stock. Gilead Sciences (GILD) stock went up by 0.99% overnight due to a research collaboration and license agreement between Kite, a Gilead Company, and Epicrispr Biotechnologies to develop next-generation cancer cell therapies using Epic Bio's gene regulation platform.
	2023-10-24	+0.76 %
Gilead Sciences (GILD) stock went up by 0.76% as the company was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, distributing over 1,000 grants totaling almost $240 million in HIV-related projects.
	2023-10-20	-0.82 %
Gilead Sciences (GILD) stock went down by -0.82% last night. The article discusses new data presented at a conference supporting Sunlenca (lenacapavir), a treatment for multi-drug resistant HIV, as an important option for heavily treatment-experienced adults. The data showed that resistance to Sunlenca occurred in a minority of participants who had inadequate adherence to their treatment regimen or were not receiving fully active antiretrovirals. The article also mentions positive perceptions of Sunlenca among healthcare professionals and coordinators involved in the study.

1
500 / page